TTX for chemotherapy-induced neuropathic pain

WEX also plans to file a protocol with the U.S. Food and Drug Administration (FDA) for our second indication, TTX for chemotherapy-induced neuropathic pain. This is a randomized, double-blind, dose-finding, placebo-controlled, multicenter study of the potential efficacy and safety of TTX in patients with CINP. This Phase II study will take place at approximately 20 sites in the United States (US), a total of 275 patients will be enrolled. Currently this clinical trial is ongoing in the United States.

Chemotherapy-induced neuropathic pain

Chemotherapy-induced neuropathic pain is an area of unmet medical need for patients treated with some of the most common cancers. The pain that is associated with chemotherapy is a condition that seriously impacts day-to-day function after therapy. A majority of patients treated with two widely-used classes of chemotherapy – the platinums (such as carboplatin and oxaliplatin) and the taxanes (such as paclitaxel and docetaxel) – experience neuropathic pain that can be debilitating and/or dose-limiting for chemotherapy treatment.